Effects of selective hyperglycemia and hyperinsulinemia on glucose transporters in fetal ovine skeletal muscle.
We measured net fetal glucose uptake rate from the placenta, shown previously to be equal to total fetal glucose utilization rate (GUR(f)) and proportional to fetal hindlimb skeletal muscle glucose utilization, under normal conditions and after 1, 2.5, and 24 h of selective hyperglycemia increasing G or selective hyperinsulinemia increasing I. We simultaneously measured the amount of Glut 1 and Glut 4 glucose transporter proteins in fetal sheep skeletal muscle. With increasing G , GUR(f) was increased approximately 40% at 1 and 2.5 h but returned to the control rate by 24 h. This transient increasing G -specific increasing GUR(f) was associated with increased plasma membrane-associated Glut 1 (4-fold) and intracellular Glut 4 (3-fold) protein beginning at 1 h. With increasing I, GUR(f) was increased approximately 70% at 1, 2.5, and 24 h. This more sustained increasing I-specific increasing GUR(f) was associated with a significant increase in Glut 4 protein (2-fold) at 2.5 h but no change in Glut 1 protein. These results show that increasing G and increasing I have independent effects on the amount of Glut 1 and Glut 4 glucose transporter proteins in ovine fetal skeletal muscle. These effects are time dependent and isoform specific and may contribute to increased glucose utilization in fetal skeletal muscle. The lack of a sustained temporal correlation between the increase in transporter proteins and glucose utilization rates indicates that subcellular localization and activity of a transporter or tissues other than the skeletal muscle contribute to net GUR(f).
Anderson
M S
MS
Perinatal Research Center and Section of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado 80262, USA. marianne.anderson@uchsc.edu
He
J
J
Flowers-Ziegler
J
J
Devaskar
S U
SU
Hay
W W
WW
D000818:Animals; D001784:Blood Gas Analysis; D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D005333:Fetus / Q000378:metabolism*; D005865:Gestational Age; D005947:Glucose / Q000493:pharmacokinetics; D015309:Glucose Clamp Technique; D051272:Glucose Transporter Type 1; D051275:Glucose Transporter Type 4; D006400:Hematocrit; D006943:Hyperglycemia / Q000139:chemically induced / Q000378:metabolism*; D006946:Hyperinsulinism / Q000139:chemically induced / Q000378:metabolism*; D007328:Insulin / Q000097:blood / Q000494:pharmacology; D009004:Monosaccharide Transport Proteins / Q000378:metabolism*; D009124:Muscle Proteins; D018482:Muscle, Skeletal / Q000166:cytology / Q000196:embryology / Q000378:metabolism*; D010920:Placenta / Q000098:blood supply / Q000378:metabolism; D021041:Placental Circulation; D011247:Pregnancy; D012508:Sarcolemma / Q000378:metabolism / Q000648:ultrastructure; D012756:Sheep; D013997:Time Factors
D001786:Blood Glucose; D051272:Glucose Transporter Type 1; D051275:Glucose Transporter Type 4; D007328:Insulin; D009004:Monosaccharide Transport Proteins; D009124:Muscle Proteins; D005947:Glucose